보고서 요약(국문)

개요
전 세계 HER2+ 위암 시장은 2022년 XX백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) XX%로 성장하여 2030년에는 XX백만 달러에 이를 것으로 예상됩니다.
HER2 과발현은 유방암에서와 마찬가지로 유전자 증폭에 의해 발생하는 흔한 분자적 이상으로 점점 더 많이 인식되고 있습니다. 위암 환자에서 HER2 과발현의 역할에 대한 증거가 증가하고 있으며, 이는 불량한 예후 및 더욱 공격적인 질병 경과와 밀접한 관련이 있습니다. HER2 양성 위암은 HER2 단백질을 과발현하는 위암의 한 유형입니다. HER2 표적 치료는 HER2 양성 위암 환자의 예후를 개선하는 것으로 나타났습니다.

시장 동향: 동인 및 제약 요인
치료 옵션의 발전
진행성 위암(GC)의 효과적인 치료를 위한 바이오마커에는 HER2 과발현, MSI/PD-L1 상태, FGFR 변이가 포함됩니다. ToGA 임상시험의 성공에도 불구하고, 항HER2 제제는 임상 결과를 크게 개선시키지 못했습니다. 미국 식품의약국(FDA)은 HER2 양성 진행성 위암 또는 위식도 접합부암 환자를 대상으로 펨브롤리주맙과 트라스투주맙 병용요법 및 화학요법의 신속 승인을 진행했습니다.
항HER2 단클론항체와 면역요법을 병용하는 것은 진행성 위암 환자의 면역 반응 저하를 극복하는 합리적인 전략입니다. T-DXd는 이전에 두 차례 치료를 받은 환자에게 효과적입니다. 위암 환자의 HER2 상태를 평가하는 것은 다양한 이질성으로 인해 어렵습니다. HER2 증폭 수준은 HER2 표적 치료의 효과를 가장 크게 볼 수 있는 환자를 선별하는 데 유용한 예측 바이오마커가 될 수 있습니다. 종양 NGS, ctDNA 및 기타 바이오마커는 항HER2 제제로부터 가장 큰 임상적 이점을 얻을 수 있는 환자군을 명확히 하는 데 도움이 될 수 있습니다.
또한, HER2 양성 위암 시장은 바이오마커 치료법의 증가, 임상 시험 증가 등 다양한 요인에 의해 성장하고 있으며, 이는 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다.
시장 동향: 제약 요인
긍정적인 성장세에도 불구하고, 전 세계 HER2 양성 위암 시장은 예측 기간 동안 시장 성장을 저해하는 여러 가지 문제에 직면해 있습니다. 건강 보험 정책의 불충분한 재정 지원과 방사선 장비의 복잡한 특성으로 인한 엄격한 규제 절차는 예측 기간 동안 위암 시장 성장을 저해할 수 있는 주요 요인입니다.
세분화 분석
전 세계 HER2 양성 위암 시장은 치료법, 병기, 최종 사용자 및 지역별로 세분화됩니다.

치료 부문에서 면역요법은 HER2 양성 위암 시장 점유율의 약 39.7%를 차지했습니다.
면역요법은 치료 부문에서 약 39.7%를 차지하며 예측 기간 동안 시장을 주도할 것으로 예상됩니다. HER2 양성 위암 치료 환경은 최근 몇 년 동안, 특히 새로운 항HER2 약물과 병용 요법의 도입으로 크게 발전했습니다. 항HER2 제제와 면역요법을 병용하는 것은 강력한 전임상적 근거를 제시하며, 임상 시험에서도 고무적인 결과가 나왔습니다. 또한, 개발 중인 다양한 치료제는 HER2 양성 질환 관리에 있어 흥미로운 시대를 열고 있습니다.
지역별 분석
북미는 2022년 시장 점유율의 약 38.4%를 차지했습니다.
북미는 위암 발병률 증가, FDA 승인, 선진 의료 기술 등의 요인으로 인해 예측 기간 동안 전체 시장 점유율의 약 38.4%를 차지하며 가장 높은 시장 점유율을 유지할 것으로 예상됩니다.

예를 들어, 위암은 암 사망 원인 3위이며, 전이성 위암의 5년 생존율은 5%에 불과합니다. 위암 환자 5명 중 1명은 HER2 양성으로 추정됩니다. 올해 미국에서는 약 27,600건의 위암 신규 환자가 진단될 것으로 예상되며, 2020년 한 해 동안 11,000명 이상이 위암으로 사망할 수 있습니다.
또한, 2020년 5월 아스트라제네카와 다이이치산쿄는 위식도 접합부암을 포함한 위암 환자 치료를 위해 미국에서 희귀의약품 지정(ODD)을 받았습니다.
COVID-19 영향 분석
COVID-19 팬데믹은 진단 및 치료 지연으로 인해 암 환자의 예후를 악화시킬 위험을 증가시켰습니다. 경험이 풍부한 다학제 의료팀은 이러한 환자들의 종양학적 치료 결과와 삶의 질을 보장하기 위해 맞춤형 치료를 제공하는 데 중요한 역할을 해왔습니다. 고소득 국가에서는 선행 항암 치료(NAT)를 시행하는 경우 위암 수술을 안전하게 연기할 수 있지만, NAT나 수술 모두 받을 수 없는 저소득 및 중소득 국가에서는 이러한 지연이 재발률 증가와 사망률 상승으로 이어질 수 있습니다.

시장 세분화
치료법별
• 면역요법
• 화학요법
• 방사선요법
• 표적치료
병기별
• 1기
• 2기
• 3기
• 4기
최종 사용자별
• 병원
• 전문 클리닉
• 외래 수술 센터
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
시장의 주요 글로벌 기업으로는 Astrazeneca, Genentech USA, Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd, Hutchison Medipharma, LintonPharm, Shanghai Henlius Biotech, Sanofi, Pfizer 등이 있습니다. 노바티스 AG를 비롯한 여러 제약회사.
주요 개발 사항
 2023년 11월, 알파맙 온콜로지와 CSPC 제약그룹은 중국 국가약품감독관리국(NMPA) 의약품평가센터(CDE)가 HER2 양성 위암(위식도 접합부암 포함) 치료를 위한 화학요법 병용요법인 KN026(HER2 이중특이항체)에 대해 혁신 치료제 지정을 승인했다고 공동 발표했습니다.

 2022년 12월, 아스트라제네카와 다이이치산쿄의 엔허투(트라스투주맙 데룩스테칸)가 이전에 트라스투주맙 기반 요법을 받은 적이 있는 진행성 HER2 양성 위암 또는 위식도 접합부(GEJ) 선암 성인 환자 치료를 위한 단독요법으로 유럽연합(EU)의 승인을 받았습니다.
이 보고서를 구매해야 하는 이유?

• 치료법, 병기, 최종 사용자 및 지역별 HER2+ 위암 시장 세분화를 시각화하고 주요 상업적 자산 및 주요 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 상업적 기회를 식별합니다.

• 모든 세그먼트를 포함한 HER2+ 위암 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 Excel 파일을 제공합니다.

본 글로벌 HER2+ 위암 시장 보고서는 약 69개의 표, 70개의 그림, 183페이지 분량입니다.
대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 연구 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global HER2+ Gastric Cancer Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX % during the forecast period 2023-2030.
HER2 overexpression is increasingly recognized as a frequent molecular abnormality, driven as in breast cancer by gene amplification. There is mounting evidence of the role of HER2 overexpression in patients with gastric cancer, and it has been solidly correlated to poor outcomes and a more aggressive disease. HER2-positive gastric cancer is a subtype of gastric cancer that overexpresses the HER2 protein. HER2-targeted therapy has been shown to improve the prognosis for patients with HER2-positive gastric cancer.
Market Dynamics: Drivers and Restraints
Advancements in treatment options
Biomarkers for effective treatment of advanced gastric cancer (GC) include HER2 overexpression, MSI/PD-L1 status, and FGFR alterations. Despite the success of the ToGA trial, anti-HER2 agents have not significantly improved clinical outcomes. The FDA has accelerated the approval of pembrolizumab in combination with trastuzumab plus chemotherapy for HER2-positive advanced gastric or GEJ cancer patients.
Combining anti-HER2 mAb with immunotherapy is a reasonable strategy to overcome immune insensitivity in AGC patients. T-DXd is effective in patients who have received two previous lines of treatment. Assessing HER2 status in GC patients is challenging due to their multiple heterogeneities. HER2 amplification level may be a predictive biomarker for selecting patients who can benefit most from HER2 targeted therapies. Tumor NGS, ctDNA, and other biomarkers may clarify the population that can derive the most clinical benefit from anti-HER2 agents.
Furthermore, the HER2+ gastric cancer market is also driven by various other factors like rise in biomarker therpaies, increase in clinical trails and others help the market to grow during the forecast period.
Market Dynamics: Restraint
Despite a positive growth trajectory, the global HER2-positive Gastric Cancer market is facing various challenges which hamper the market growth during the forecast period. The lack of adequate financial assistance from health insurance policies and stringent regulatory procedures for approving the complex nature of radiation devices are the major factors that can hamper the gastric cancer market growth over the forecast period.
Segment Analysis
The global HER2+ gastric cancer market is segmented based on therapy, stage, end-user and region.
The immunotherapy from the therapy segment accounted for approximately 39.7% of the HER2+ gastric cancer market share
The immunotherapy from the therapy segment accounted for approximately 39.7% and is expected to dominate during the forecast period. The treatment landscape of HER2-positive gastric cancer has evolved over recent years, especially with the introduction of novel anti-HER2 drugs and combination strategies. The use of immunotherapy in combination with anti-HER2 agents demonstrates a strong preclinical rationale, and clinical trials have produced encouraging results. Additionally, the diverse therapeutic drugs under development mark an exciting era in the management of HER2-positive disease.
Geographical Analysis
North America accounted for approximately 38.4% of the market share in 2022
North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the factors like the rising prevalence of gastric cancer, FDA approvals, advanced healthcare technology and others that help the region to be highest market share during the forecast period.
For instance, Gastric cancer is the third leading cause of cancer mortality with a five-year survival rate of 5% for metastatic disease. Approximately one in five gastric cancers are considered HER2 positive. An estimated 27,600 new cases of gastric cancer will be diagnosed this year and the disease could lead to more than 11,000 deaths in the US in 2020.
Moreover, in May 2020, AstraZeneca and Daiichi Sankyo Company, Limited was granted Orphan Drug Designation (ODD) in the US for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.
COVID-19 Impact Analysis
The COVID-19 pandemic has put cancer patients at risk of adverse outcomes due to delays in diagnosis and treatment. Experienced multidisciplinary teams have had a critical role in tailoring management to ensure oncological outcomes and quality of life for these patients. While in high-income countries gastric cancer surgical treatment could be safely delayed provided that neoadjuvant treatment (NAT) was administered, in low-medium-income countries where patients could not receive either NAT or surgery, these delays could lead to increased recurrence rates and excess mortality.

Market Segmentation
By Therapy
• Immunotherapy
• Chemotherapy
• Radiation Therapy
• Targeted Therapy
By Stage
• Stage I
• Stage II
• Stage III
• Stage IV
By End User
• Hospitals
• Speciality Clinics
• Ambulatory Surgical Centers
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Astrazeneca, Genentech USA, Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd, Hutchison Medipharma, LintonPharm, Shanghai Henlius Biotech, Sanofi, Pfizer, Novartis AG and among others.
Key Developments
 In November 2023, Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd jointly stated, that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) granted a Breakthrough Therapy designation to KN026 (HER2 bispecific antibody) combined with chemotherapy for the treatment of HER2-positive gastric cancer (including gastroesophageal junction cancer).
 In December 2022, AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
Why Purchase the Report?
• To visualize the global HER2+ gastric cancer market segmentation based on therapy, stage, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of HER2+ gastric cancer market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global HER2+ gastric cancer market report would provide approximately 69 tables, 70 figures and 183 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Therapy
3.2. Snippet by Stage
3.3. Snippet by End User
3.4. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Advancements in the treatment options
4.1.1.2. Rise in awareness
4.1.2. Restraints
4.1.2.1. Regulatory challenges
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Therapy
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
7.1.2. Market Attractiveness Index, By Therapy
7.2. Immunotherapy*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Chemotherapy
7.4. Radiation Therapy
7.5. Targeted Therapy
8. By Stage
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
8.1.2. Market Attractiveness Index, By Stage
8.2. Stage I*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Stage II
8.4. Stage III
8.5. Stage IV
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Speciality Clinics
9.4. Ambulatory Surgical Centers
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.5.1. China
10.5.5.2. India
10.5.5.3. Japan
10.5.5.4. Australia
10.5.5.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Astrazeneca*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Genentech USA
12.3. Bristol-Myers Squibb
12.4. Ono Pharmaceutical Co. Ltd
12.5. Hutchison Medipharma
12.6. LintonPharm
12.7. Shanghai Henlius Biotech
12.8. Sanofi
12.9. Pfizer
12.10. Novartis AG
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Astrazeneca, 4.	Key Developments, Genentech USA, Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd, Hutchison Medipharma, LintonPharm, Shanghai Henlius Biotech, Sanofi, Pfizer, Novartis AG

표 목록 (Tables)

List of Tables

Table 1 Global HER2+ Gastric Cancer Market Value, By Therapy, 2022, 2026 & 2030 (US$ Million)

Table 2 Global HER2+ Gastric Cancer Market Value, By Stage, 2022, 2026 & 2030 (US$ Million)

Table 3 Global HER2+ Gastric Cancer Market Value, By End User, 2022, 2026 & 2030 (US$ Million)

Table 4 Global HER2+ Gastric Cancer Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global HER2+ Gastric Cancer Market Value, By Therapy, 2022, 2026 & 2030 (US$ Million)

Table 6 Global HER2+ Gastric Cancer Market Value, By Therapy, 2021-2030 (US$ Million)

Table 7 Global HER2+ Gastric Cancer Market Value, By Stage, 2022, 2026 & 2030 (US$ Million)

Table 8 Global HER2+ Gastric Cancer Market Value, By Stage, 2021-2030 (US$ Million)

Table 9 Global HER2+ Gastric Cancer Market Value, By End User, 2022, 2026 & 2030 (US$ Million)

Table 10 Global HER2+ Gastric Cancer Market Value, By End User, 2021-2030 (US$ Million)

Table 11 Global HER2+ Gastric Cancer Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global HER2+ Gastric Cancer Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America HER2+ Gastric Cancer Market Value, By Therapy, 2021-2030 (US$ Million)

Table 14 North America HER2+ Gastric Cancer Market Value, By Stage, 2021-2030 (US$ Million)

Table 15 North America HER2+ Gastric Cancer Market Value, By End User, 2021-2030 (US$ Million)

Table 16 North America HER2+ Gastric Cancer Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America HER2+ Gastric Cancer Market Value, By Therapy, 2021-2030 (US$ Million)

Table 18 South America HER2+ Gastric Cancer Market Value, By Stage, 2021-2030 (US$ Million)

Table 19 South America HER2+ Gastric Cancer Market Value, By End User, 2021-2030 (US$ Million)

Table 20 South America HER2+ Gastric Cancer Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe HER2+ Gastric Cancer Market Value, By Therapy, 2021-2030 (US$ Million)

Table 22 Europe HER2+ Gastric Cancer Market Value, By Stage, 2021-2030 (US$ Million)

Table 23 Europe HER2+ Gastric Cancer Market Value, By End User, 2021-2030 (US$ Million)

Table 24 Europe HER2+ Gastric Cancer Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific HER2+ Gastric Cancer Market Value, By Therapy, 2021-2030 (US$ Million)

Table 26 Asia-Pacific HER2+ Gastric Cancer Market Value, By Stage, 2021-2030 (US$ Million)

Table 27 Asia-Pacific HER2+ Gastric Cancer Market Value, By End User, 2021-2030 (US$ Million)

Table 28 Asia-Pacific HER2+ Gastric Cancer Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa HER2+ Gastric Cancer Market Value, By Therapy, 2021-2030 (US$ Million)

Table 30 Middle East & Africa HER2+ Gastric Cancer Market Value, By Stage, 2021-2030 (US$ Million)

Table 31 Middle East & Africa HER2+ Gastric Cancer Market Value, By End User, 2021-2030 (US$ Million)

Table 32 Astrazeneca: Overview

Table 33 Astrazeneca: Product Portfolio

Table 34 Astrazeneca: Key Developments

Table 35 Genentech USA: Overview

Table 36 Genentech USA: Product Portfolio

Table 37 Genentech USA: Key Developments

Table 38 Bristol-Myers Squibb: Overview

Table 39 Bristol-Myers Squibb: Product Portfolio

Table 40 Bristol-Myers Squibb: Key Developments

Table 41 Ono Pharmaceutical Co. Ltd: Overview

Table 42 Ono Pharmaceutical Co. Ltd: Product Portfolio

Table 43 Ono Pharmaceutical Co. Ltd: Key Developments

Table 44 Hutchison Medipharma: Overview

Table 45 Hutchison Medipharma: Product Portfolio

Table 46 Hutchison Medipharma: Key Developments

Table 47 LintonPharm: Overview

Table 48 LintonPharm: Product Portfolio

Table 49 LintonPharm: Key Developments

Table 50 Shanghai Henlius Biotech: Overview

Table 51 Shanghai Henlius Biotech: Product Portfolio

Table 52 Shanghai Henlius Biotech: Key Developments

Table 53 Sanofi: Overview

Table 54 Sanofi: Product Portfolio

Table 55 Sanofi: Key Developments

Table 56 Pfizer: Overview

Table 57 Pfizer: Product Portfolio

Table 58 Pfizer: Key Developments

Table 59 Novartis AG: Overview

Table 60 Novartis AG: Product Portfolio

Table 61 Novartis AG: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global HER2+ Gastric Cancer Market Value, 2021-2030 (US$ Million)

Figure 2 Global HER2+ Gastric Cancer Market Share, By Therapy, 2022 & 2030 (%)

Figure 3 Global HER2+ Gastric Cancer Market Share, By Stage, 2022 & 2030 (%)

Figure 4 Global HER2+ Gastric Cancer Market Share, By End User, 2022 & 2030 (%)

Figure 5 Global HER2+ Gastric Cancer Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global HER2+ Gastric Cancer Market Y-o-Y Growth, By Therapy, 2022-2030 (%)

Figure 7 Chemotherapy HER2+ Gastric Cancer Market Value, 2021-2030 (US$ Million)

Figure 8 Immunotherapy HER2+ Gastric Cancer Market Value, 2021-2030 (US$ Million)

Figure 9 Radiation Therapy HER2+ Gastric Cancer Market Value, 2021-2030 (US$ Million)

Figure 10 Targeted Therapy HER2+ Gastric Cancer Market Value, 2021-2030 (US$ Million)

Figure 11 Global HER2+ Gastric Cancer Market Y-o-Y Growth, By Stage, 2022-2030 (%)

Figure 12 Stage I Stage in Global HER2+ Gastric Cancer Market Value, 2021-2030 (US$ Million)

Figure 13 Stage II Stage in Global HER2+ Gastric Cancer Market Value, 2021-2030 (US$ Million)

Figure 14 Stage III Stage in Global HER2+ Gastric Cancer Market Value, 2021-2030 (US$ Million)

Figure 15 Stage IV Stage in Global HER2+ Gastric Cancer Market Value, 2021-2030 (US$ Million)

Figure 16 Global HER2+ Gastric Cancer Market Y-o-Y Growth, By End User, 2022-2030 (%)

Figure 17 Hospitals End User in Global HER2+ Gastric Cancer Market Value, 2021-2030 (US$ Million)

Figure 18 Speciality Clinics End User in Global HER2+ Gastric Cancer Market Value, 2021-2030 (US$ Million)

Figure 19 Ambulatory Surgical Centers End User in Global HER2+ Gastric Cancer Market Value, 2021-2030 (US$ Million)

Figure 20 Others End User in Global HER2+ Gastric Cancer Market Value, 2021-2030 (US$ Million)

Figure 21 Global HER2+ Gastric Cancer Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 22 North America HER2+ Gastric Cancer Market Value, 2021-2030 (US$ Million)

Figure 23 Asia-Pacific HER2+ Gastric Cancer Market Value, 2021-2030 (US$ Million)

Figure 24 Europe HER2+ Gastric Cancer Market Value, 2021-2030 (US$ Million)

Figure 25 South America HER2+ Gastric Cancer Market Value, 2021-2030 (US$ Million)

Figure 26 Middle East and Africa HER2+ Gastric Cancer Market Value, 2021-2030 (US$ Million)

Figure 27 North America HER2+ Gastric Cancer Market Value, 2021-2030 (US$ Million)

Figure 28 North America HER2+ Gastric Cancer Market Share, By Therapy, 2022 & 2030 (%)

Figure 29 North America HER2+ Gastric Cancer Market Share, By Stage, 2022 & 2030 (%)

Figure 30 North America HER2+ Gastric Cancer Market Share, By End User, 2022 & 2030 (%)

Figure 31 North America HER2+ Gastric Cancer Market Share, By Country, 2022 & 2030 (%)

Figure 32 South America HER2+ Gastric Cancer Market Value, 2021-2030 (US$ Million)

Figure 33 South America HER2+ Gastric Cancer Market Share, By Therapy, 2022 & 2030 (%)

Figure 34 South America HER2+ Gastric Cancer Market Share, By Stage, 2022 & 2030 (%)

Figure 35 South America HER2+ Gastric Cancer Market Share, By End User, 2022 & 2030 (%)

Figure 36 South America HER2+ Gastric Cancer Market Share, By Country, 2022 & 2030 (%)

Figure 37 Europe HER2+ Gastric Cancer Market Value, 2021-2030 (US$ Million)

Figure 38 Europe HER2+ Gastric Cancer Market Share, By Therapy, 2022 & 2030 (%)

Figure 39 Europe HER2+ Gastric Cancer Market Share, By Stage, 2022 & 2030 (%)

Figure 40 Europe HER2+ Gastric Cancer Market Share, By End User, 2022 & 2030 (%)

Figure 41 Europe HER2+ Gastric Cancer Market Share, By Country, 2022 & 2030 (%)

Figure 42 Asia-Pacific HER2+ Gastric Cancer Market Value, 2021-2030 (US$ Million)

Figure 43 Asia-Pacific HER2+ Gastric Cancer Market Share, By Therapy, 2022 & 2030 (%)

Figure 44 Asia-Pacific HER2+ Gastric Cancer Market Share, By Stage, 2022 & 2030 (%)

Figure 45 Asia-Pacific HER2+ Gastric Cancer Market Share, By End User, 2022 & 2030 (%)

Figure 46 Asia-Pacific HER2+ Gastric Cancer Market Share, By Country, 2022 & 2030 (%)

Figure 47 Middle East & Africa HER2+ Gastric Cancer Market Value, 2021-2030 (US$ Million)

Figure 48 Middle East & Africa HER2+ Gastric Cancer Market Share, By Therapy, 2022 & 2030 (%)

Figure 49 Middle East & Africa HER2+ Gastric Cancer Market Share, By Stage, 2022 & 2030 (%)

Figure 50 Middle East & Africa HER2+ Gastric Cancer Market Share, By End User, 2022 & 2030 (%)

Figure 51 Astrazeneca: Financials

Figure 52 Genentech USA: Financials

Figure 53 Bristol-Myers Squibb: Financials

Figure 54 Ono Pharmaceutical Co. Ltd: Financials

Figure 55 Hutchison Medipharma: Financials

Figure 56 LintonPharm: Financials

Figure 57 Shanghai Henlius Biotech: Financials

Figure 58 Sanofi: Financials

Figure 59 Pfizer: Financials

Figure 60 Novartis AG: Financials

글로벌 HER2+ 위암 시장 – 2023-2030

Global HER2+ Gastric Cancer Market - 2023-2030